Attorney Docket No. MYCOLOGX-04875





# RECEIVED

OCT 1-2 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**TECH CENTER 1600/2900** 

In re Application of: Claude P. Selitrennikoff et al.

Serial No.:

09/866,209

5/25/2001

Group No.: Examiner:

1645

to be assigned

Filed: Entitled:

Methods For The Identification of Antimicrobial

Compounds

# INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Assistant Commissioner for Patents Washington, D.C. 20231

#### CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: October 1, 2001

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.


Dated:

October 1, 2001

Kamrin T. Macknight

Registration No. 38,230

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 415/904-6500



## UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 12 2001

In re Application of: Claude P. Selitrennikoff et al.

**TECH CENTER 1600/290** 

Serial No.:

09/866,209

Group No.: 1645

to be assigned

Examiner:

Filed: Entitled: 5/25/01 Methods For The Identification of

**Antimicrobial Compounds** 

# INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

### CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on

October 1, 2001.

#### Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications are referred to in the body of the specification:

- Anaissie, "Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review," Clin. Infect. Dis., 14(Suppl 1):S43-S53 [1992];
- Ausubel et al. (eds.), Current Protocols in Molecular Biology, Volumes 1-4, (New York: John Wiley & Sons, Inc.) [1994] title and copyright pages supplied;
- Badet et al., "Glucosamine synthetase from Escherichia coli: Purification, properties, and glutamine-utilizing site location," Biochemistry 26:1940-1948 [1987];

- Beck-Sague *et al.*, "Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990," *J. Infect. Dis.*, 167:1247-1251 [1993];
- Borgia, "Roles of the orlA, tsE, and bimG genes of Aspergillus nidulans in chitin synthesis," J. Bacteriol., 174:384-389 [1992];
- Boschman et al., "Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center," Antimicrob. Agents Chemother., 42:734-738 [1998];
- Boshart *et al.*, "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," *Cell* 41:521-530 [1985];
- Bow, "Invasive fungal infections in patients receiving intensive cytotoxic therapy for cancer," *Br. J. Haematol.*, 101(Suppl 1):1-4 [1998];
- Brooks et al, (ed.), Jawetz, Melnick & Adelberg's Medical Microbiology, 19th edition, (Norwalk, CT: Appleton & Lange) p. 150 [1991];
- Bulawa, "Genetics and molecular biology of chitin synthesis in fungi," *Annu. Rev. Microbiol.*, 47:505-534 [1993];
- Cohen *et al.*, "Nonchromosomal antibiotic resistance in bacteria: genetic transformation of *Escherichia coli* by R-factor DNA," *Proc. Natl. Acad. Sci. USA* 69:2110-2114 [1972];
- Cole, "Basic biology of fungi," In Baron (ed.) Medical Microbiology, 4th edition, (Galveston, TX: University of Texas Medical Branch) pp. 903-911 [1996];
- Daniels *et al.*, "Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells," *J. Clinical Invest.*, 97(5):1235-1241 [1996];
- Decker et al., "Structure-activity relationships of the nikkomycins," J. Gen. Microbiol., 137:1805-1813 [1991];
- Denning et al., "Pulmonary aspergillosis in the acquired immunodeficiency syndrome," New Eng. J. Med., 324:654-662 [1992];
- Dijkema *et al.*, "Cloning and expression of the chromosomal immune interferon gene of the rat," *EMBO J.*, 4:761-767 [1985];

- Dixon and Walsh, "Antifungal Agents," In Baron (ed.) Medical Microbiology,
   4th edition, (Galveston, TX: University of Texas Medical Branch) pp. 926-932
   [1996];
- Endo *et al.*, "Feedback inhibition of L-glutamine D-fructose 6-phosphate amidotransferase by uridine diphosphate N-acetylglucosamine in *Neurospora crassa*," *J. Bacteriol.*, 103:588-594 [1970];
- Espinel-Ingroff et al., "Antifungal agents and susceptibility tests," in Murray et al., (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1640-1652 [1999];
- Etchebehere and Da Costa Maia, "Phosphorylation-dependent regulation of amidotransferase during development of *Blastocladiella emersonii*," *Arch. Biochem. Biophys.*, 272:301-310 [1989];
- Etchebehere et al., "Development regulation of hexosamine biosynthesis by protein phosphatases 2A and 2C in Blastocladiella emersonii," J. Bacteriol., 175:5022-5027 [1993];
- Ferraro and Jorgensen, "Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation," In Murray *et al.*, (eds.), *Manual of Clinical Microbiology*, 7th edition, (Washington, DC: ASM Press) pp. 1593-1600 [1999];
- Goodwin et al., "A nationwide survey of clinical laboratory methodologies for fungal infections," J. Med. Vet. Mycol., 30:153-160 [1992];
- Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," Proc. Natl. Acad. Sci. USA 79:6777-6781 [1982];
- Graham and van der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," *Virol.*, 52:456-467 [1973];
- Graybill, "The future of antifungal therapy," *Clin. Infect. Dis.*, 22(Suppl 2):S166-S178 [1996];
- Hanahan, "Studies on transformation of *Escherichia coli* with plasmids," *J. Mol. Biol.*, 166:557-580 [1983];

- Hanson et al., "Synergy between cilofungin and amphotericin B in a murine model of candidiasis," Antimicrob. Agents Chemother., 35:1334-1337 [1991];
- Inderlied and Salfinger, "Antimycobacterial agents and susceptibility tests," In Murray et al., (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1601-1623 [1999];
- Jorgensen et al., "Antibacterial susceptibility tests: dilution and disk diffusion methods," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1526-1543 [1999];
- Katz and Rosenberger, "A mutation in *Aspergillus nidulans* producing hyphal walls which lack chitin," *Biochim. Biophys. Acta.*, 208:452-460 [1970];
- Kim et al., "Use of the human elongation factor 1α promoter as a versatile and efficient expression system," Gene 91:217-223 [1990];
- Kornfeld, "Studies on L-glutamine, D-fructose 6-phosphate amidotransferase,"
   J. Biol. Chem., 242:3135-3141 [1967];
- Leloir and Cardini, "The biosynthesis of glucosamine," *Biochim. Biophys. Acta.*, 12:15-22 [1953];
- Lortholary *et al.*, "Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases," *Amer. J. Med.*, 95:177-187 [1993];
- Maniatis *et al.*, "Regulation of inducible and tissue-specific gene expression," Science 236:1237-1244 [1987];
- McGinnis and Tyring, "Introduction to Mycology," In Baron (ed.), Medical
  Microbiology, 4th edition, (Galveston TX: University of Texas Medical Branch)
  pp. 893-902 [1996];
- McKnight et al., "Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase," J. Biol. Chem.,
   267:25208-25212 [1992];
- Mellado et al., "A multigene family related to chitin synthase genes of yeast in the opportunistic pathogen Aspergillus fumigatus," Mol. Gen. Genet., 246:353-359 [1995];

- Meunier, et al., "Candidemia in immunocompromised patients," Clin. Infect.
   Dis., 14(Suppl 1):S120-S125 [1992];
- Milewski et al., "Antifungal peptides with novel specific inhibitors of glucosamine 6-phosphate synthase," Drugs Exp. Clin. Res., 14:461-465 [1988];
- Milewski et al., "Mechanism of action of anticandidal dipeptides containing inhibitors of glucosamine-6-phosphate synthase," Antimicrob. Agents Chemo., 35:36-43 [1991];
- Milewski *et al.*, "Oligomeric structure and regulation of *Candida albicans* glucosamine-6-phosphate synthase," *J. Biol. Chem.*, 274(7):4000-4008 [1999];
- Miller et al., "Pulmonary aspergillosis in patients with AIDS," Chest 105:37-44 [1994];
- Mitchell, "Opportunistic mycoses," In Joklik et al. [eds], Zinsser Microbiology,
   (Norwalk, CT: Appleton, Century-Crofts) pp. 1183-1197 [1984];
- Mizushima and Nagata, "pEF-BOS, a powerful mammalian expression vector,"

  Nuc. Acids. Res., 18:5322 [1990];
- National Committee for Clinical Laboratory Standards (NCCLS), "Reference Method for Broth Dilution Susceptibility Testing of Yeasts: Tentative Standard," Publication M27-T [1995];
- Polis and Kovacs, "Fungal Infections in Patients with the Acquired Immunodeficiency Syndrome," in DeVita et al. (eds), <u>AIDS: Biology</u>, <u>Diagnosis, Treatment, and Prevention</u>, 4th ed., (Philadelphia, PA: Lippincott-Raven Publishers) pp. 231-244 [1997];
- Russell and Srb, "A study of L-glutamine:D-fructose 6-phosphate amidotransferase in certain developmental mutants of *Neurospora crassa*,"
   Molec. Gen. Genet., 129:77-86 [1974];
- Sambrook et al. (eds.), Molecular Cloning: A Laboratory Manual, 2nd edition, Volumes 1-3, (NY: Cold Spring Harbor Laboratory Press) [1989] title and copyright pages supplied;
- Selitrennikoff and Ostroff, "Emerging therapeutic cell wall targets in fungal infections," *Emerging Therapeutic Targets* 3:53-72 [1999];

- Selitrennikoff and Sonneborn, "Post-translational control of de Novo cell wall formation during Blastocladiella emersonii zoospore germination," Develop. Biol., 54:37-51 [1976];
- Selitrennikoff and Sonneborn, "The last two pathway-specific enzyme activities
  of hexosamine biosynthesis are present in *Blastocladiella emersonii* zoospores
  prior to germination," *Biochim. Biophys. Acta.*, 451:408-416 [1976];
- Selitrennikoff et al., "Regulation of the hexosamine biosynthetic pathway in the water mold Blastocladiella emersonii: sensitivity to endproduct inhibition is dependent upon the life cycle phase," Proc. Natl. Acad. Sci. USA 77:5998-6002 [1980];
- Sessegolo et al., "Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated in Brazil from 1988 to 1992," J. Clin. Microbiol., 32:906-911 [1994];
- Sigler and Kennedy, "Aspergillus, Fusarium, and other opportunistic moniliaceous fungi," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington DC: ASM Press) pp. 1213-1241 [1999];
- Smith et al., "Isolation and characterization of the GFA1 gene encoding the glutamine:fructose-6-phosphate amidotransferase of Candida albicans," J. Bacteriol., 178:2320-2327 [1996];
- Tenover and McGowan, "Reasons for the emergence of antibiotic resistance," Am. J. Med. Sci., 311:9-16 [1996];
- Tokumura and Horie, "Kinetics of nikkomycin Z degradation in aqueous solution and in plasma," *Biol. Pharm. Bull.*, 20:577-580 [1997];
- Turnidge and Jorgensen, "Antimicrobial susceptibility testings: general considerations," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1469-1473 [1999];
- Uetsuki et al., "Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1α," J. Biol. Chem., 264:5791-5798
   [1989];

- Van Noorden and Butcher, "The involvement of superoxide anions in the nitro blue tetrazolium chloride reduction mediated by NADH and phenazine methosulfate," Anal. Biochem., 176:170-174 [1989];
- Voss *et al.*, "The role of enhancers in the regulation of cell-type-specific transcriptional control," *Trends Biochem. Sci.*, 11:287-289 [1986];
- Walsh and Dixon, "Spectrum of mycoses," In Baron (ed.), Medical Microbiology, 4th edition, (Galveston, TX: University of Texas Medical Branch) pp. 919-925 [1996];
- Warnock, "Fungal infections in neutropenia: current problems and chemotherapeutic control," J. Antimicrob. Chemother., 41:95-105 [1998];
- Warren and Hazen, "Candida, Cryptococcus, and other yeasts of medical importance," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1184-1199 [1999];
- Watzele and Tanner, "Cloning of the glutamine:fructose-6-phosphate amidotransferase gene from yeast," J. Biol. Chem., 264:8753-8758 [1989];
- White, "Antifungal drug resistance in Candida albicans," ASM News 63:427-433 [1997];
- White et al., "Clinical, cellular, and molecular factors that contribute to antifungal drug resistance," Clin. Microbiol. Rev., 11:382-402 [1998];
- Winterburn and Phelps, "Purification and some kinetic properties of rat liver glucosamine synthetase," *Biochem. J.*, 121:701-709 [1971]; and
- Zalkin, "Glucosamine-6-phosphate synthase," Methods Enzymol., 113:278-281
   [1985].

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

PATENT Attorney Docket No. MYCOLOGX-04875

R

: )(;

Dated: October 1, 2001

TECH CENTER 1600/2900

Kamrin T. MacKnight Registration No. 38,230

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 415/904-6500 FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: MYCOLOGX-04875

Serial No.: 09/866,209

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheets If Necessary)

Applicant: Claude P. Selitrennikoff et al.

		(Use Several Sheets	If Necessary)						
(37 CFR § 1.98(b))					Filing Date: 5/25/2001 Group Art Un				
			1	U.S. PATENT DOC	CUMENTS				) <b>3</b>
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applic	ant / Patentee	Class	Subclass		Date
			:					<u> </u>	
		FC	REIGN PATENTS O	R PUBLISHED FO	REIGN PATENT APPL	ICATIONS			
		Document		_				Translation	
		Number	Publication Date	Country	/ Patent Office	Class	Subclass	Yes	No
							<u> </u>	<u> </u>	
		OTHER I	DOCUMENTS (Includ	ling Author, Title, E	Date, Relevant Pages, Pla	ace of Publication)	<u> </u>		
	1	Anaissie, "Opportur 1):S43-S53 [1992]	nistic mycoses in the in	mmunocompromised	host: experience at a ca	ancer center and re	eview," <i>Clin. Infe</i>	ct. Dis., 14	(Suppl
	2	Ausubel et al. (eds.), Current Protocols in Molecular Biology, Volumes 1-4, (New York: John Wiley & Sons, Inc.) [1994] title and copyright pages supplied							
	3	Badet et al., "Glucosamine synthetase from Escherichia coli: Purification, properties, and glutamine-utilizing site location," Biochemistry 26:1940-1948 [1987]							
	4	Beck-Sague et al.,"3 167:1247-1251 [199		pidemiology of nosc	ocomial fungal infection	s in the United Sta	ites, 1980-1990,"	J. Infect. L	is.,
	5	Borgia, "Roles of the	ne- <i>orIA; tsE,</i> -and- <i>bimG</i>	genes of Aspergillu	is nidulans in chitin syn	thesis," J. Bacterio	ol., 174:384-389 [	1992]	
	6		Thirteen-year evolution ter," Antimicrob. Agent		in yeast isolates and pre 34-738 [1998]	evalence of resistar	nt strains carried b	y cancer p	atients
į	7	Boshart et al., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," Cell 41:521-530 [1985]							
	8	Bow, "Invasive fun	gal infections in patien	ts receiving intensiv	e cytotoxic therapy for	cancer," Br. J. Ha	ematol., 101(Sup	01 1):1-4 [1	998]
<u> </u>	9	Brooks et al, (ed.),	Jawetz, Melnick & Ade	elberg's Medical M	icrobiology, 19th edition	ı, (Norwalk, CT: A	Appleton & Lange	) p. 150 [1	991]
	10	Bulawa, "Genetics a	and molecular biology	of chitin synthesis i	n fungi," <i>Annu. Rev. Mic</i>	crobiol., 47:505-53	34 [1993]		
	11	Cohen et al., "None Acad. Sci. USA 69:		resistance in bacter	ia: genetic transformatio	on of <i>Escherichia</i>	coli by R-factor D	NA," <i>Proc</i>	. Natl.
	12	Cole, "Basic biolog 903-911 [1996]	y of fungi," In Baron (	(ed.) Medical Micro	biology, 4th edition, (Ga	alveston, TX: Univ	ersity of Texas M	ledical Bra	nch) pj
	13	Daniels <i>et al.</i> , "Glu 97(5):1235-1241 [1		phate amidotransfera	ase activity in cultured h	numan skeletal mu	scle cells," J. Clir	ical Invest	.,
	14	Decker et al., "Strue	cture-activity relationsh	nips of the nikkomy	cins," J. Gen. Microbiol	., 137:1805-1813	[1991]		
	15	Denning et al., "Pul	monary aspergillosis in	n the acquired immu	unodeficiency syndrome	," New Eng. J. Me	ed., 324:654-662	[1992]	
	16	Dijkema et al., "Clo	oning and expression o	f the chromosomal	immune interferon gene	of the rat," EMBC	) J., 4:761-767 [1	985]	
	17	Dixon and Walsh, Branch) pp. 926-93		Baron (ed.) Medica	al Microbiology, 4th edi	ition, (Galveston,	ΓX: University of	Texas Med	dical
	18		ack inhibition of L-glu " J. Bacteriol., 103:588		-phosphate amidotransfo	erase by uridine di	phosphate N-acet	ylglucosam	ine in
	19		al., "Antifungal agents ASM Press) pp. 1640-1		ests," in Murray et al., (	eds.), Manual of C	Clinical Microbiolo	ogy, 7th ed	ition,
	20	Etchebehere and Da emersonii," Arch. B	a Costa Maia, "Phosphoiochem. Biophys., 272	orylation-dependent :301-310 [1989]	regulation of amidotran	sferase during dev	elopment of Blass	ocladiella	
<b>,</b>	21	Etchebehere et al., Bacteriol., 175:5022	"Development regulation 2-5027 [1993]	on of hexosamine b	iosynthesis by protein pl	hosphatases 2A an	d 2C in <i>Blastocla</i>	diella emei	rsonii,"
Examiner:					Date Considered:				

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

S. Department of Commerce fatent and Trademark Office

Attorney Docket No.: MYCOLOGX-04875

Serial No.: 09/866,209

INFORMATION DISCUSSING STATEMENT BY APPLICANT (Use Several Steels in necessary)

Applicant: Claude P. Selitrennikoff et al.

(37 CFR § 1.9	8(b))	(Ose Several successary)	Filing Date: 5/25/2001	Group Art Unit: 1645			
		OTHER DOCUMENTS (Including Author, Title, Da	ate, Relevant Pages, Place of Publication)				
-	22	Ferraro and Jorgensen, "Susceptibility testing instrumentation a Murray et al., (eds.), Manual of Clinical Microbiology, 7th ed					
	23	Goodwin et al., "A nationwide survey of clinical laboratory methodologies for fungal infections," J. Med. Vet. Mycol., 30:153-160 [1992]					
	24	Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," Proc. Natl. Acad. Sci. USA 79:6777-6781 [1982]					
<del></del>	25	Graham and van der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," Virol., 52:456-467 [1973]					
	26 ·	Graybill, "The future of antifungal therapy," Clin. Infect. Dis.,	n. Infect. Dis., 22(Suppl 2):S166-S178 [1996]				
	Hanahan, "Studies on transformation of Escherichia coli with plasmids," J. Mol. Biol., 166:557-580 [1983]						
	Hanson et al., "Synergy between cilofungin and amphotericin B in a murine model of candidiasis," Antimicrob. Agents Ch. 1337 [1991]						
	29	Inderlied and Salfinger, "Antimycobacterial agents and susceptibility tests," In Murray et al., (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1601-1623 [1999]  Jorgensen et al., "Antibacterial susceptibility tests: dilution and disk diffusion methods," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1526-1543 [1999]					
	30						
	31	Katz and Rosenberger, "A mutation in Aspergillus nidulans producing hyphal walls which lack chitin," Biochim. Biophys. Acta., 208:452-460 [1970]					
	32	Kim et al., "Use of the human elongation factor 1α promoter as a versatile and efficient expression system," Gene-91:217-223 [1990]					
	33	Kornfeld, "Studies on L-glutamine, D-fructose 6-phosphate am	nidotransferase," J. Biol. Chem., 242:3135-3	3141 [1967]			
	34	Leloir and Cardini, "The biosynthesis of glucosamine," Biochin	m. Biophys. Acta., 12:15-22 [1953]				
ı	35	Lortholary et al., "Invasive aspergillosis in patients with acquir 187 [1993]	red immunodeficiency syndrome: report of	33 cases," Amer. J. Med., 95:177-			
	36	Maniatis et al., "Regulation of inducible and tissue-specific get	ne expression," Science 236:1237-1244 [19	987]			
Ų.	37	McGinnis and Tyring, "Introduction to Mycology," In Baron (ed.), <i>Medical Microbiology</i> , 4th edition, (Galveston TX: University of Texa Medical Branch) pp. 893-902 [1996]					
	38	McKnight et al., "Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase J. Biol. Chem., 267:25208-25212 [1992]					
	39	Mellado et al., "A multigene family related to chitin synthase genes of yeast in the opportunistic pathogen Aspergillus fumigatus," Mol. Genet., 246:353-359 [1995]					
	40	feunier, et al., "Candidemia in immunocompromised patients," Clin. Infect. Dis., 14(Suppl 1):S120-S125 [1992]					
	41	Milewski et al., "Antifungal peptides with novel specific inhibitors of glucosamine 6-phosphate synthase," Drugs Exp. Clin. Res., 14:461-46: [1988]					
	42	Milewski et al., "Mechanism of action of anticandidal dipeptides containing inhibitors of glucosamine-6-phosphate synthase," Antima Agents Chemo., 35:36-43 [1991]					
	43	Milewski et al., "Oligomeric structure and regulation of Candia 4008 [1999]	da albicans glucosamine-6-phosphate synth	nase," J. Biol. Chem., 274(7):4000-			
	44	Miller et al., "Pulmonary aspergillosis in patients with AIDS,"	Chest 105:37-44 [1994]				
	45	Mitchell, "Opportunistic mycoses," In Joklik et al. [eds], Zinsser Microbiology, (Norwalk, CT: Appleton, Century-Crofts) pp. 1183-11 [1984]					
	46	Mizushima and Nagata, "pEF-BOS, a powerful mammalian ex	pression vector," Nuc. Acids. Res., 18:5322	2 [1990]			
	47	National Committee for Clinical Laboratory Standards (NCCLS Tentative Standard," Publication M27-T [1995]	S), "Reference Method for Broth Dilution S	Susceptibility Testing of Yeasts:			
	48	Polis and Kovacs, "Fungal Infections in Patients with the Acqu Diagnosis, Treatment, and Prevention, 4th ed., (Philadelphia, P					
Examiner:			Date Considered:				

FORM PTO-1449 (Modified)

(37 CFR § 1.98(b))

Department of Commerce Patent and Trademark Office

Attorney Docket No.: MYCOLOGX-04875

Serial No.: 09/866,209

INFORMATION DISCLOSURE STITUTE TENT BY APPLICANT (Use Several Sheets II Necessary)

with next communication to applicant.

Applicant: Claude P. Selitrennikoff et al.

Filing Date: 5/25/2001 Group Art Unit: 1645 OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

ie		OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)
	49	Russell and Srb, "A study of L-glutamine:D-fructose 6-phosphate amidotransferase in certain developmental mutants of Neurospora crassa," Molec. Gen. Genet., 129:77-86 [1974]
	50	Sambrook et al. (eds.), Molecular Cloning: A Laboratory Manual, 2nd edition, Volumes 1-3, (NY: Cold Spring Harbor Laboratory Press) [1989] title and copyright pages supplied
	51	Selitrennikoff and Ostroff, "Emerging therapeutic cell wall targets in fungal infections," Emerging Therapeutic Targets 3:53-72 [1999]
	52	Selitrennikoff and Sonneborn, "Post-translational control of de Novo cell wall formation during Blastocladiella emersonii zoospore germination," Develop. Biol., 54:37-51 [1976]
	53	Selitrennikoff and Sonneborn, "The last two pathway-specific enzyme activities of hexosamine biosynthesis are present in <i>Blastocladiella emersonii</i> zoospores prior to germination," <i>Biochim. Biophys. Acta.</i> , 451:408-416 [1976]
	54	Selitrennikoff et al., "Regulation of the hexosamine biosynthetic pathway in the water mold Blastocladiella emersonii: sensitivity to endproduct inhibition is dependent upon the life cycle phase," Proc. Natl. Acad. Sci. USA 77:5998-6002 [1980]
	55	Sessegolo et al., "Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated in Brazil from 1988 to 1992," J. Clin. Microbiol., 32:906-911 [1994]
	56	Sigler and Kennedy, "Aspergillus, Fusarium, and other opportunistic moniliaceous fungi," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington DC: ASM Press) pp. 1213-1241 [1999]
	57	Smith et al., "Isolation and characterization of the GFA1 gene encoding the glutamine:fructose-6-phosphate amidotransferase of Candida albicans," J. Bacteriol., 178:2320-2327 [1996]
	58	Tenover and McGowan, "Reasons for the emergence of antibiotic resistance," Am. J. Med. Sci., 311:9-16 [1996]
	59	Tokumura and Horie, "Kinetics of nikkomycin Z degradation in aqueous solution and in plasma," Biol. Pharm. Bull., 20:577-580 [1997]
	60	Turnidge and Jorgensen, "Antimicrobial susceptibility testings: general considerations," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1469-1473 [1999]
.1	61	Uetsuki et al., "Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1α," J. Biol. Chem., 264:5791-5798 [1989]
•	62	Van Noorden and Butcher, "The involvement of superoxide anions in the nitro blue tetrazolium chloride reduction mediated by NADH and phenazine methosulfate," <i>Anal. Biochem.</i> , 176:170-174 [1989]
	63	Voss et al., "The role of enhancers in the regulation of cell-type-specific transcriptional control," Trends Biochem. Sci., 11:287-289 [1986]
	64	Walsh and Dixon, "Spectrum of mycoses," In Baron (ed.), <i>Medical Microbiology</i> , 4th edition, (Galveston, TX: University of Texas Medical Branch) pp. 919-925 [1996]
	65	Warnock, "Fungal infections in neutropenia: current problems and chemotherapeutic control," J. Antimicrob. Chemother., 41:95-105 [1998]
	66	Warren and Hazen, "Candida, Cryptococcus, and other yeasts of medical importance," In Murray et al. (eds.), Manual of Clinical Microbiology, 7th edition, (Washington, DC: ASM Press) pp. 1184-1199 [1999]
	67	Watzele and Tanner, "Cloning of the glutamine:fructose-6-phosphate amidotransferase gene from yeast," J. Biol. Chem., 264:8753-8758 [1989]
	68	White, "Antifungal drug resistance in Candida albicans," ASM News 63:427-433 [1997]
	68 69	
	†	
	69	White et al., "Clinical, cellular, and molecular factors that contribute to antifungal drug resistance," Clin. Microbiol. Rev., 11:382-402 [1998]